Wall Street brokerages expect Miragen Therapeutics, Inc. (NASDAQ:MGEN) to post ($0.32) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Miragen Therapeutics’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.28). Miragen Therapeutics posted earnings per share of ($7.72) in the same quarter last year, which would indicate a positive year-over-year growth rate of 95.9%. The company is scheduled to announce its next earnings results on Friday, March 23rd.
On average, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.35) per share for the current financial year, with EPS estimates ranging from ($1.62) to ($0.98). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.72) to ($1.29). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Miragen Therapeutics.
A number of equities analysts have recently commented on MGEN shares. Wedbush reissued a “buy” rating and set a $19.00 price target on shares of Miragen Therapeutics in a report on Friday, December 1st. Cann started coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 price target for the company. Zacks Investment Research cut Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Chardan Capital restated a “buy” rating on shares of Miragen Therapeutics in a research report on Tuesday, January 16th. Finally, B. Riley assumed coverage on Miragen Therapeutics in a research report on Friday, January 5th. They set a “buy” rating and a $15.50 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. Miragen Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $16.46.
In related news, Director Thomas E. Hughes sold 12,000 shares of the business’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $8.00, for a total transaction of $96,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 44.40% of the company’s stock.
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its position in Miragen Therapeutics by 4.7% during the 4th quarter. BlackRock Inc. now owns 574,917 shares of the medical research company’s stock worth $5,997,000 after acquiring an additional 25,704 shares during the last quarter. Virtu Financial LLC grew its position in Miragen Therapeutics by 372.8% during the 4th quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock worth $541,000 after acquiring an additional 40,920 shares during the last quarter. Bank of New York Mellon Corp grew its position in Miragen Therapeutics by 67.1% during the 4th quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock worth $478,000 after acquiring an additional 18,374 shares during the last quarter. SG Americas Securities LLC bought a new stake in Miragen Therapeutics during the 3rd quarter worth $250,000. Finally, Aveo Capital Partners LLC bought a new stake in Miragen Therapeutics during the 4th quarter worth $279,000. Institutional investors and hedge funds own 22.59% of the company’s stock.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.